MARKET

BLRX

BLRX

Biolinerx
NASDAQ
0.5753
-0.0377
-6.15%
After Hours: 0.5899 +0.0146 +2.54% 19:15 04/25 EDT
OPEN
0.6193
PREV CLOSE
0.6130
HIGH
0.6230
LOW
0.5606
VOLUME
636.13K
TURNOVER
0
52 WEEK HIGH
2.530
52 WEEK LOW
0.5606
MARKET CAP
45.99M
P/E (TTM)
-0.6096
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BLRX last week (0415-0419)?
Weekly Report · 3d ago
BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 04/17 17:44
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
TipRanks · 04/17 15:05
BioLineRx Enhances Multiple Myeloma Treatment
TipRanks · 04/17 12:27
Weekly Report: what happened at BLRX last week (0408-0412)?
Weekly Report · 04/15 10:17
Biolinerx: Report of foreign issuer
Press release · 04/10 12:05
BIOLINERX ACCESSES SECOND TRANCHE OF $20 MILLION UNDER PREVIOUSLY ANNOUNCED $40 MILLION NON-DILUTIVE DEBT FINANCING AGREEMENT
Reuters · 04/10 11:00
Weekly Report: what happened at BLRX last week (0401-0405)?
Weekly Report · 04/08 10:20
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.